Pharmalittle: We're reading about concerns over a rare disease drug, pharma payments to docs, and more

Hospital group sues — again — to halt Trump administration's 340B rebate pilot

Following the release of an open letter addressing potential safety concerns regarding a rare disease medication marketed by Neurocrine Biosciences, both patient advocates and medical experts are expressing heightened apprehension about the associated risks of the treatment. The drug, approved for the management of Prader-Willi syndrome—condition characterized by an extreme sense of hunger—has been implicated in the deaths of seven individuals and the hospitalization of nearly one hundred others since its approval 18 months ago for the therapy known as Vykat XR.

Although the reports of these fatalities and hospitalizations submitted to regulatory authorities do not establish a direct causal link—many instances involve patients with intricate medical histories and concurrent medications—some experts assert that the existing evidence is compelling enough to indicate that Vykat is inflicting significant harm.

Pharma Payments and Prescribing Practices

A recent Cochrane review, which examined numerous studies, indicates that financial gifts and payments from pharmaceutical companies to physicians contribute to inappropriate prescribing practices and an increase in the volume of prescriptions written, ultimately likely driving up healthcare expenses. Additionally, pharmaceutical marketing strategies targeting healthcare providers may also augment inappropriate prescribing tendencies, thus further increasing the quantity of prescriptions written and escalating prescription costs. However, the review suggests that policies aimed at managing conflicts of interest between pharmaceutical companies and healthcare practitioners may enhance prescribing practices.